摘要
环孢素A(CsA)是临床常用的免疫抑制剂,并在再生障碍性贫血(AA)及异基因造血干细胞移植(allo-HSCT)急性移植物抗宿主病(aGVHD)中获得较确切的疗效。CsA药代动力学及药效学个体差异大,治疗窗窄。CsA有效血药浓度及监测点受多种因素影响。临床科室需动态检测各个因素的临床意义,尤其注意检测CsA时间点、与临床疗效、预后等的相关性研究。
Cyclosporine A （CsA） is currently used in clinical as an immune inhibitor, which has gain more exact curative effects in the treatment of aplastic anemia and allogeneic hematopoietic stem cell transplantation for acute graft-versus-host disease. Because of the individual differences in pharmacokinetic and pharmacodynamic of CsA, CsA has the narrow therapeutic window. The effective blood drug concentration and monitoring of CsA is influenced by many factors. It is necessary for the clinical departments to dynamically detect the clinical significance of the various factors, especially paying attention to the correlation research of detection time point, the clinical efficacy and prognosis, etc.
出处
《中华临床医师杂志（电子版）》
CAS
2014年第1期104-107,共4页
Chinese Journal of Clinicians(Electronic Edition)
基金
山东省优秀中青年科学家科研奖励基金(BS2013SF030)
山东省自然科学基金(ZR2012HL38
2009ZRA09006)
山东省医药卫生科技发展计划项目(2011HW077)
关键词
贫血
再生障碍性
造血干细胞移植
血药浓度
环孢素A
Anemia, aplastic
Hematopoietic stem cell transplantation
Blood drugconcentration
Cyclosporine A
